New functions for the matrix metalloproteinases in cancer progression (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Bissell, M. J. & Radisky, D. Putting tumours in context. Nature Rev. Cancer 1, 46–54 (2001).
  Article CAS Google Scholar
• Werb, Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91, 439–442 (1997).
  CAS PubMed Google Scholar
• Brooks, P. C. et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85, 683–693 (1996).Localization of active MMP-2, secreted by stromal cells, to the cell surface of invasive cells by binding to αvβ3 integrin is necessary for invasive behaviour. Similar results relating to the importance of invasion, angiogenesis and TGF-β processing of tethering MMP-9 to the cell surface by binding to CD44 were reported in references 5 and 28.
  CAS PubMed Google Scholar
• Yu, Q. & Stamenkovic, I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13, 35–48 (1999).
  CAS PubMed PubMed Central Google Scholar
• Yu, W.-H., Woessner, J. F. Jr, McNeish, J. D. & Stamenkovic, I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16, 307–323 (2002).
  CAS PubMed PubMed Central Google Scholar
• Sternlicht, M. D. & Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463–516 (2001).
  CAS PubMed PubMed Central Google Scholar
• Strongin, A. Y. et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 5331–5338 (1995).
  CAS PubMed Google Scholar
• Deryugina, E. I. et al. MT1-MMP initiates activation of pro-MMP-2 and integrin αvβ3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res. 263, 209–223 (2001).
  CAS PubMed Google Scholar
• Morrison, C. J. et al. Cellular activation of MMP-2 (Gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J. Biol. Chem. 276, 47402–47410 (2001).
  CAS PubMed Google Scholar
• Sottrup-Jensen, L. & Birkedal-Hansen, H. Human fibroblast collagenase-α-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian α-macroglobulins. J. Biol. Chem. 264, 393–401 (1989).
  CAS PubMed Google Scholar
• Yang, Z., Strickland, D. K. & Bornstein, P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 276, 8403–8408 (2001).
  CAS PubMed Google Scholar
• Bein, K. & Simons, M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem. 275, 32167–32173 (2000).
  CAS PubMed Google Scholar
• Rodriguez-Manzaneque, J. C. et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 98, 12485–12490 (2001).
  CAS PubMed PubMed Central Google Scholar
• Taraboletti, G. et al. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 14, 1674–1676 (2000).
  CAS PubMed Google Scholar
• Edwards, D. R. in Matrix Metalloproteinase Inhibitors in Cancer Therapy (eds Clendeninn, N. J. & Appelt, K.) 67–84 (Humana Press, Totowa, New Jersey, 2001).
  Google Scholar
• Wang, Z., Juttermann, R. & Soloway, P. D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem. 275, 26411–26415 (2000).
  CAS PubMed Google Scholar
• Mott, J. D. et al. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J. Biol. Chem. 275, 1384–1390 (2000).
  CAS PubMed Google Scholar
• Netzer, K. O., Suzuki, K., Itoh, Y., Hudson, B. G. & Khalifah, R. G. Comparative analysis of the noncollagenous NC1 domain of type IV collagen: identification of structural features important for assembly, function, and pathogenesis. Protein Sci. 7, 1340–1351 (1998).
  CAS PubMed PubMed Central Google Scholar
• Oh, J. et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789–800 (2001).Reports that deficiency of an MMP inhibitor, RECK, is embryonic lethal, due to a defect in vascular development. Also shows that the blood vessels in tumours that overexpress RECK have a reduced branching phenotype.
  CAS PubMed Google Scholar
• Streuli, C. Extracellular matrix remodelling and cellular differentiation. Curr. Opin. Cell. Biol. 11, 634–640 (1999).
  CAS PubMed Google Scholar
• Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G. & Quaranta, V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277, 225–228 (1997).Shows, together with reference 100 , that cleavage of laminin-5 by MMPs triggers the migration of cells by unmasking a cryptic site that might act as a ligand for an unidentified cellular receptor.
  CAS PubMed Google Scholar
• Xu, J. et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154, 1069–1080 (2001).Shows that a cryptic site within collagen type IV that is exposed following proteinase cleavage promotes angiogenesis and tumour growth, probably by interacting with αvβ3 integrin. This cryptic site is detected in blood vessels from tumours but not normal tissue.
  CAS PubMed PubMed Central Google Scholar
• Manes, S. et al. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem. 272, 25706–25712 (1997).
  CAS PubMed Google Scholar
• Manes, S. et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem. 274, 6935–6945 (1999).
  CAS PubMed Google Scholar
• Whitelock, J. M., Murdoch, A. D., Iozzo, R. V. & Underwood, P. A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 271, 10079–10086 (1996).
  CAS PubMed Google Scholar
• Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281–1284 (1998).
  CAS PubMed Google Scholar
• Yu, Q. & Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163–176 (2000).
  PubMed PubMed Central Google Scholar
• Levi, E. et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl Acad. Sci. USA 93, 7069–7074 (1996).
  CAS PubMed PubMed Central Google Scholar
• Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., Arribas, J. & Baselga, J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59, 1196–1201 (1999).
  CAS PubMed Google Scholar
• Vecchi, M., Rudolph-Owen, L. A., Brown, C. L., Dempsey, P. J. & Carpenter, G. Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J. Biol. Chem. 273, 20589–20595 (1998).
  CAS PubMed Google Scholar
• Nath, D., Williamson, N. J., Jarvis, R. & Murphy, G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Sci. 114, 1213–1220 (2001).
  CAS PubMed Google Scholar
• Noe, V. et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 114, 111–118 (2001).
  CAS PubMed Google Scholar
• Kajita, M. et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 153, 893–904 (2001).Reports that CD44 is shed by MMP-14 and that mutation of the cleavage site inhibits migration.
  CAS PubMed PubMed Central Google Scholar
• Deryugina, E. I., Ratnikov, B. I., Postnova, T. I., Rozanov, D. V. & Strongin, A. Y. Processing of integrin αV subunit by MT1–MMP stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of FAK. J. Biol. Chem. 2001 Nov 27; [epub ahead of print].
• Coussens, L. M. & Werb, Z. Matrix metalloproteinases and the development of cancer. Chem. Biol. 3, 895–904 (1996).
  CAS PubMed Google Scholar
• Masson, R. et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140, 1535–1541 (1998).
  CAS PubMed PubMed Central Google Scholar
• Itoh, T. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58, 1048–1051 (1998).
  CAS PubMed Google Scholar
• Itoh, T. et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis 17, 177–181 (1999).
  CAS PubMed Google Scholar
• Sternlicht, M. D. et al. The stromal proteinase MMP-3/ stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137–146 (1999).Shows, together with reference 95 , that active MMP-3 changes the phenotype of mammary epithelial cells to mesenchymal-like cells, and that the E-cadherin–β-catenin complex is involved in this regulation. Expression of an MMP, even when expressed only in the early stages of cancer development, is also sufficient to initiate tumour formation.
  CAS PubMed PubMed Central Google Scholar
• Ha, H. Y. et al. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res 61, 984–990 (2001).
  CAS PubMed Google Scholar
• Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000).In a transgenic mouse model of skin cancer, the reduced carcinogenesis in mice that are deficient for MMP9 can be completely restored by bone-marrow transplantation of MMP9 -expressing cells. Tumours that arise in the absence of MMP9 are of a more advanced stage than those that arise in wild-type mice.
  CAS PubMed PubMed Central Google Scholar
• Yang, W. et al. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 91, 1277–1283 (2001).
  CAS PubMed Google Scholar
• Takeha, S. et al. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn. J. Cancer Res. 88, 72–81 (1997).
  CAS PubMed PubMed Central Google Scholar
• Jiang, Y. et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res. 61, 2365–2370 (2001).
  CAS PubMed Google Scholar
• Hayakawa, T., Yamashita, K., Ohuchi, E. & Shinagawa, A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107, 2373–2379 (1994).
  CAS PubMed Google Scholar
• Yoshiji, H. et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int. J. Cancer 75, 81–87 (1998).
  CAS PubMed Google Scholar
• Gururajan, R. et al. Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. Genome Res. 8, 929–939 (1998).
  CAS PubMed PubMed Central Google Scholar
• Llano, E. et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 59, 2570–2576 (1999).
  CAS PubMed Google Scholar
• Crawford, H. C. et al. The PEA3 subfamily of Ets transcription factors synergizes with β- catenin–LEF-1 to activate matrilysin transcription in intestinal tumors. Mol. Cell Biol. 21, 1370–1383 (2001).
  CAS PubMed PubMed Central Google Scholar
• Sun, Y. et al. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J. Biol. Chem. 274, 11535–11540 (1999).
  CAS PubMed Google Scholar
• Sun, Y. et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J. Biol. Chem. 275, 11327–11332 (2000).
  CAS PubMed Google Scholar
• Polette, M. et al. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 424, 641–645 (1994).
  CAS PubMed Google Scholar
• Kanamori, Y. et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 59, 4225–4227 (1999).
  CAS PubMed Google Scholar
• Ye, S. et al. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res. 61, 1296–1298 (2001).
  CAS PubMed Google Scholar
• Zhu, Y., Spitz, M. R., Lei, L., Mills, G. B. & Wu, X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 61, 7825–7829 (2001).
  CAS PubMed Google Scholar
• Ye, S. et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 271, 13055–13060 (1996).
  CAS PubMed Google Scholar
• Biondi, M. L. et al. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin. Chem. 46, 2023–2024 (2000).
  CAS PubMed Google Scholar
• Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000).MMP-9 controls tumour angiogenesis by increasing the bioavailability of VEGF, and is expressed by stromal cells but not by cancer cells. MMP-2 also influences tumour growth but not angiogenesis. Invasion is not affected by MMP-2 or MMP-9.
  CAS PubMed Google Scholar
• Agrez, M., Chen, A., Cone, R. I., Pytela, R. & Sheppard, D. The αvβ6 integrin promotes proliferation of colon carcinoma cells through a unique region of the β6 cytoplasmic domain. J. Cell Biol. 127, 547–556 (1994).
  CAS PubMed Google Scholar
• Derynck, R., Akhurst, R. J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117–129 (2001).
  CAS PubMed Google Scholar
• Reed, J. C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11, 68–75 (1999).
  CAS PubMed Google Scholar
• Alexander, C. M., Howard, E. W., Bissell, M. J. & Werb, Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J. Cell Biol. 135, 1669–1677 (1996).
  CAS PubMed Google Scholar
• Witty, J. P., Lempka, T., Coffey, R. J. Jr & Matrisian, L. M. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res. 55, 1401–1406 (1995).
  CAS PubMed Google Scholar
• Sympson, C. J. et al. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J. Cell Biol. 125, 681–693 (1994).
  CAS PubMed Google Scholar
• Powell, W. C., Fingleton, B., Wilson, C. L., Boothby, M. & Matrisian, L. M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9, 1441–1447 (1999).
  CAS PubMed Google Scholar
• Mitsiades, N., Yu, W.-H., Poulaki, V., Tsokos, M. & Stamenkovic, I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61, 577–581 (2001).
  CAS PubMed Google Scholar
• Wu, E. et al. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J. Cell Biochem. 82, 549–555 (2001).
  CAS PubMed Google Scholar
• Boulay, A. et al. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 61, 2189–2193 (2001).
  CAS PubMed Google Scholar
• Baserga, R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19, 5574–5581 (2000).
  CAS PubMed Google Scholar
• Ishizuya-Oka, A. et al. Requirement for matrix metalloproteinase stromelysin-3 in cell migration and apoptosis during tissue remodeling in Xenopus laevis. J. Cell Biol. 150, 1177–1188 (2000).
  CAS PubMed PubMed Central Google Scholar
• Vu, T. H. et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411–422 (1998).
  CAS PubMed PubMed Central Google Scholar
• Herren, B., Levkau, B., Raines, E. W. & Ross, R. Cleavage of β-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol. Biol. Cell 9, 1589–1601 (1998).
  CAS PubMed PubMed Central Google Scholar
• Ilan, N., Mohsenin, A., Cheung, L. & Madri, J. A. PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J. 15, 362–372 (2001).
  CAS PubMed Google Scholar
• Steinhusen, U. et al. Cleavage and shedding of E-cadherin after induction of apoptosis. J. Biol. Chem. 276, 4972–4980 (2001).
  CAS PubMed Google Scholar
• Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
  CAS PubMed Google Scholar
• Martin, D. C. et al. Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab. Invest. 79, 225–234 (1999).
  CAS PubMed Google Scholar
• Li, H. et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum. Gene Ther. 12, 515–526 (2001).
  CAS PubMed Google Scholar
• Gatto, C. et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin. Cancer Res. 5, 3603–3607 (1999).
  CAS PubMed Google Scholar
• Seandel, M., Noack-Kunnmann, K., Zhu, D., Aimes, R. T. & Quigley, J. P. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 97, 2323–2332 (2001).
  CAS PubMed Google Scholar
• Kolb, C., Mauch, S., Peter, H. H., Krawinkel, U. & Sedlacek, R. The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. Immunol. Lett. 57, 83–88 (1997).
  CAS PubMed Google Scholar
• Fang, J. et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl Acad. Sci. USA 97, 3884–3889 (2000).
  CAS PubMed PubMed Central Google Scholar
• Galvez, B. G., Matias-Roman, S., Albar, J. P., Sanchez-Madrid, F. & Arroyo, A. G. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem. 276, 37491–37500 (2001).
  CAS PubMed Google Scholar
• Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R. & Weiss, S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365–377 (1998).
  CAS PubMed Google Scholar
• Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052–4057 (2000).
  CAS PubMed PubMed Central Google Scholar
• Dong, Z., Kumar, R., Yang, X. & Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801–810 (1997).The first paper to show that MMP cleavage can produce anti-angiogenic fragments of ECM components.
  CAS PubMed Google Scholar
• Cornelius, L. A. et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161, 6845–6852 (1998).
  CAS PubMed Google Scholar
• Gorrin-Rivas, M. J. et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin. Cancer Res. 6, 1647–1654 (2000).
  CAS PubMed Google Scholar
• Ferreras, M., Felbor, U., Lenhard, T., Olsen, B. R. & Delaisse, J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 486, 247–251 (2000).
  CAS PubMed Google Scholar
• O'Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315–328 (1994).
  CAS PubMed Google Scholar
• O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).
  CAS PubMed Google Scholar
• Kim, Y. M. et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60, 5410–5413 (2000).
  CAS PubMed Google Scholar
• Koolwijk, P. et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 97, 3123–3131 (2001).
  CAS PubMed Google Scholar
• Ahonen, M., Baker, A. H. & Kahari, V. M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 58, 2310–2315 (1998).
  CAS PubMed Google Scholar
• Lochter, A. et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861–1872 (1997).
  CAS PubMed PubMed Central Google Scholar
• Belien, A. T., Paganetti, P. A. & Schwab, M. E. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J. Cell Biol. 144, 373–384 (1999).
  CAS PubMed PubMed Central Google Scholar
• Deryugina, E. I., Luo, G. X., Reisfeld, R. A., Bourdon, M. A. & Strongin, A. Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res. 17, 3201–3210 (1997).
  CAS PubMed Google Scholar
• Ala-Aho, R., Johansson, N., Baker, A. H. & Kahari, V. M. Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int. J. Cancer 97, 283–289 (2002).
  CAS PubMed Google Scholar
• Hua, J. & Muschel, R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56, 5279–5284 (1996).
  CAS PubMed Google Scholar
• Koshikawa, N., Giannelli, G., Cirulli, V., Miyazaki, K. & Quaranta, V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 148, 615–624 (2000).
  CAS PubMed PubMed Central Google Scholar
• Birchmeier, C., Birchmeier, W. & Brand-Saberi, B. Epithelial–mesenchymal transitions in cancer progression. Acta Anat. (Basel.) 156, 217–226 (1996).
  CAS Google Scholar
• Nakahara, H. et al. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc. Natl Acad. Sci. USA 94, 7959–7964 (1997).
  CAS PubMed PubMed Central Google Scholar
• Bourguignon, L. Y. et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell Physiol. 176, 206–215 (1998).
  CAS PubMed Google Scholar
• Kim, J., Yu, W., Kovalski, K. & Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94, 353–362 (1998).
  CAS PubMed Google Scholar
• Tsunezuka, Y. et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res. 56, 5678–5683 (1996).
  CAS PubMed Google Scholar
• Koop, S. et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54, 4791–4797 (1994).
  CAS PubMed Google Scholar
• Krüger, A., Fata, J. E. & Khokha, R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90, 1993–2000 (1997).
  PubMed Google Scholar
• Krüger, A. et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16, 2419–2423 (1998).
  PubMed Google Scholar
• Soloway, P. D., Alexander, C. M., Werb, Z. & Jaenisch, R. Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. Oncogene 13, 2307–2314 (1996).
  CAS PubMed Google Scholar
• Coussens, L. M. & Werb, Z. Inflammatory cells and cancer: think different! J. Exp. Med. 193, F23–F26 (2001).
  CAS PubMed PubMed Central Google Scholar
• Sheu, B.-C. et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61, 237–242 (2001).Shows that MMPs can suppress the proliferation of activated T lymphocytes by shedding the interleukin-2 receptor-α from their surface.
  CAS PubMed Google Scholar
• Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118–1122 (2001).
  CAS PubMed Google Scholar
• Kataoka, H. et al. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of α1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am. J. Pathol. 154, 457–468 (1999).
  CAS PubMed PubMed Central Google Scholar
• Opdenakker, G., Van den Steen, P. E. & Van Damme, J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22, 571–579 (2001).
  CAS PubMed Google Scholar
• McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206 (2000).MMPs regulate the inflammatory response by cleaving CCL7 — a chemokine that is involved in leukocyte recruitment — thereby converting it to an antagonist of its receptors.
  CAS PubMed Google Scholar
• McQuibban, G. A. et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503–43508 (2001).
  CAS PubMed Google Scholar
• Müller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001).
  PubMed Google Scholar
• Yonemura, Y. et al. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. J. Exp. Clin. Cancer Res. 20, 205–212 (2001).
  CAS PubMed Google Scholar
• Kondraganti, S. et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. 60, 6851–6855 (2000).
  CAS PubMed Google Scholar
• Noonberg, S. B. & Benz, C. C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59, 753–767 (2000).
  CAS PubMed Google Scholar
• Elkin, M. et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin. Cancer Res. 5, 1982–1988 (1999).
  CAS PubMed Google Scholar
• Silletti, S., Kessler, T., Goldberg, J., Boger, D. L. & Cheresh, D. A. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl Acad. Sci. USA 98, 119–124 (2001).Characterizes a compound that inhibits tumour growth by specifically disrupting the protein–protein interaction between MMP-2 and αvβ3 integrin, without any effects on MMP-2 activity in general.
  CAS PubMed Google Scholar
• Liu, S., Netzel-Arnett, S., Birkedal-Hansen, H. & Leppla, S. H. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 60, 6061–6067 (2000).
  CAS PubMed Google Scholar
• Celiker, M. Y. et al. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene 20, 4337–4343 (2001).
  CAS PubMed Google Scholar
• Brand, K. et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res. 60, 5723–5730 (2000).
  CAS PubMed Google Scholar
• Koivunen, E. et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol. 17, 768–774 (1999).Characterizes a peptide inhibitor that specifically inhibits the gelatin-binding MMPs, but not other MMPs.
  CAS Google Scholar
• Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C. & Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447–3455 (2001).
  CAS PubMed Google Scholar
• Hirte, H. et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann. Oncol. 11, 1579–1584 (2000).
  CAS PubMed Google Scholar
• Moore, M. J. et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12–9566 (9566) in patients (PTS) with advanced pancreatic cancer. ASCO Online [online] (cited 05 Feb 2002), 〈http://www.asco.org/prof/me/html/00abstracts/gic/m_930.htm〉 (2000).
• Hidalgo, M. & Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl Cancer Inst. 93, 178–193 (2001).
  CAS PubMed Google Scholar
• Boissier, S. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60, 2949–2954 (2000).
  CAS PubMed Google Scholar
• Gingras, D. et al. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 21, 145–155 (2001).
  CAS PubMed Google Scholar
• Falardeau, P., Champagne, P., Poyet, P., Hariton, C. & Dupont, E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 28, 620–625 (2001).
  CAS PubMed Google Scholar
• Garbisa, S. et al. Tumor invasion: molecular shears blunted by green tea. Nature Med. 5, 1216 (1999).
  CAS PubMed Google Scholar
• Thun, M. J., Namboodiri, M. M. & Heath, C. W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325, 1593–1596 (1991).
  CAS PubMed Google Scholar
• Jiang, M. C., Liao, C. F. & Lee, P. H. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem. Biophys. Res. Commun. 282, 671–677 (2001).
  CAS PubMed Google Scholar
• Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812 (1999).
  CAS PubMed Google Scholar
• Eccles, S. A. et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56, 2815–2822 (1996).
  CAS PubMed Google Scholar
• Kheradmand, F. & Werb, Z. Shedding light on sheddases: role in growth and development. Bioessays 24, 8–12 (2002).
  CAS PubMed Google Scholar
• Tang, B. L. ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 33, 33–44 (2001).
  CAS PubMed Google Scholar
• Olsen, B. R. & Ninomiya, Y. in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 380–408 (Oxford Univ. Press, Oxford, UK, 1999).
  Google Scholar
• Maeshima, Y. et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140–143 (2002).
  CAS PubMed Google Scholar
• Sasaki, T. & Timpl, R. in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 434–443 (Oxford Univ. Press, Oxford, UK, 1999).
  Google Scholar
• Hynes, R. in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 422–425 (Oxford Univ. Press, Oxford, UK, 1999).
  Google Scholar
• Gustafsson, E. & Fassler, R. Insights into extracellular matrix functions from mutant mouse models. Exp. Cell Res. 261, 52–68 (2000).
  CAS PubMed Google Scholar
• Lander, A. D. in Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins (eds Kreis, T. & Vale, R.) 351–356 (Oxford Univ. Press, Oxford, UK, 1999).
  Google Scholar
• Cossins, J., Dudgeon, T. J., Catlin, G., Gearing, A. J. & Clements, J. M. Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem. Biophys. Res. Commun. 228, 494–498 (1996).
  CAS PubMed Google Scholar
• Marchenko, G. N. et al. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem. J. 356, 705–718 (2001).
  CAS PubMed PubMed Central Google Scholar
• Pei, D., Kang, T. & Qi, H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem. 275, 33988–33997 (2000).
  CAS PubMed Google Scholar
• Ohnishi, J. et al. Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase-23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development. Mol. Endocrinol. 15, 747–764 (2001).
  CAS PubMed Google Scholar
• D'Armiento, J. et al. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol. Cell Biol. 15, 5732–5739 (1995).
  CAS PubMed PubMed Central Google Scholar
• Colandrea, T. D., D'Armiento, J., Kesari, K. V. & Chada, K. K. Collagenase induction promotes mouse tumorigenesis by two independent pathways. Mol. Carcinog. 29, 8–16 (2000).
  CAS PubMed Google Scholar
• Matrisian, L. M. Cancer biology: extracellular proteinases in malignancy. Curr. Biol. 9, R776–R778 (1999).
  CAS PubMed Google Scholar
• Rudolph-Owen, L. A., Chan, R., Muller, W. J. & Matrisian, L. M. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. 58, 5500–5506 (1998).
  CAS PubMed Google Scholar
• Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L. & Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl Acad. Sci. USA 94, 1402–1407 (1997).
  CAS PubMed PubMed Central Google Scholar
• Martin, D. C., Rüther, U., Sanchez-Sweatman, O. H., Orr, F. W. & Khokha, R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene 13, 569–576 (1996).
  CAS PubMed Google Scholar
• Buck, T. B., Yoshiji, H., Harris, S. R., Bunce, O. R. & Thorgeirsson, U. P. The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice. Ann. NY Acad. Sci. 878, 732–735 (1999).
  CAS PubMed Google Scholar
• Goss, K. J., Brown, P. D. & Matrisian, L. M. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int. J. Cancer 78, 629–635 (1998).
  CAS PubMed Google Scholar
• Coussens, L. M., Fingleton, B. & Matrisian, L. M. Status of matrix metalloproteinase inhibitors as anti-cancer therapeutics. Science (in the press).